These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9040014)

  • 81. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.
    Dunbar PR; Smith CL; Chao D; Salio M; Shepherd D; Mirza F; Lipp M; Lanzavecchia A; Sallusto F; Evans A; Russell-Jones R; Harris AL; Cerundolo V
    J Immunol; 2000 Dec; 165(11):6644-52. PubMed ID: 11086110
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
    Meidenbauer N; Marienhagen J; Laumer M; Vogl S; Heymann J; Andreesen R; Mackensen A
    J Immunol; 2003 Feb; 170(4):2161-9. PubMed ID: 12574389
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Human melanoma-specific peptide antigens recognized by HLA-A2 restricted tumor-infiltrating lymphocytes].
    Ge H; Bao Z
    Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):658-61. PubMed ID: 9275546
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
    Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
    Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.
    Reynolds SR; Oratz R; Shapiro RL; Hao P; Yun Z; Fotino M; Vukmanović S; Bystryn JC
    Int J Cancer; 1997 Sep; 72(6):972-6. PubMed ID: 9378560
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.
    Benlalam H; Labarrière N; Linard B; Derré L; Diez E; Pandolfino MC; Bonneville M; Jotereau F
    Eur J Immunol; 2001 Jul; 31(7):2007-15. PubMed ID: 11449353
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Lejeune F; Speiser D; Rimoldi D; Cerundolo V; Dietrich PY; Cerottini JC; Romero P
    J Immunol; 2000 Jul; 165(1):533-8. PubMed ID: 10861093
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1.
    Wölfel T; Schneider J; Meyer Zum Büschenfelde KH; Rammensee HG; Rötzschke O; Falk K
    Int J Cancer; 1994 May; 57(3):413-8. PubMed ID: 8169004
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
    Le Gal FA; Prevost-Blondel A; Lengagne R; Bossus M; Farace F; Chaboissier A; Gras-Masse H; Engelhard VH; Guillet JG; Gahéry-Ségard H
    Int J Cancer; 2002 Mar; 98(2):221-7. PubMed ID: 11857412
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
    Derré L; Ferber M; Touvrey C; Devevre E; Zoete V; Leimgruber A; Romero P; Michielin O; Lévy F; Speiser DE
    J Immunol; 2007 Dec; 179(11):7635-45. PubMed ID: 18025209
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
    Valmori D; Lévy F; Miconnet I; Zajac P; Spagnoli GC; Rimoldi D; Liénard D; Cerundolo V; Cerottini JC; Romero P
    J Immunol; 2000 Jan; 164(2):1125-31. PubMed ID: 10623865
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter.
    Kurnick JT; Ramirez-Montagut T; Boyle LA; Andrews DM; Pandolfi F; Durda PJ; Butera D; Dunn IS; Benson EM; Gobin SJ; van den Elsen PJ
    J Immunol; 2001 Aug; 167(3):1204-11. PubMed ID: 11466335
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
    Cormier JN; Salgaller ML; Prevette T; Barracchini KC; Rivoltini L; Restifo NP; Rosenberg SA; Marincola FM
    Cancer J Sci Am; 1997; 3(1):37-44. PubMed ID: 9072306
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
    Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
    J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals.
    Jäger E; Ringhoffer M; Arand M; Karbach J; Jäger D; Ilsemann C; Hagedorn M; Oesch F; Knuth A
    Melanoma Res; 1996 Dec; 6(6):419-25. PubMed ID: 9013479
    [TBL] [Abstract][Full Text] [Related]  

  • 98. SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.
    Park J; Talukder AH; Lim SA; Kim K; Pan K; Melendez B; Bradley SD; Jackson KR; Khalili JS; Wang J; Creasy C; Pan BF; Woodman SE; Bernatchez C; Hawke D; Hwu P; Lee KM; Roszik J; Lizée G; Yee C
    Cancer Immunol Res; 2017 Aug; 5(8):618-629. PubMed ID: 28630054
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
    Kim CJ; Prevette T; Cormier J; Overwijk W; Roden M; Restifo NP; Rosenberg SA; Marincola FM
    J Immunother; 1997 Jul; 20(4):276-86. PubMed ID: 9220317
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.
    Rivoltini L; Loftus DJ; Squarcina P; Castelli C; Rini F; Arienti F; Belli F; Marincola FM; Geisler C; Borsatti A; Appella E; Parmiani G
    Crit Rev Immunol; 1998; 18(1-2):55-63. PubMed ID: 9419448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.